
|Videos|March 29, 2022
Major considerations and updates in immunotherapy for advanced prostate cancer
Author(s)Urology Times staff
“People's concepts of immunotherapy are unfortunately quite distorted. It is not just about checkpoint inhibitors,” says Susan F. Slovin, MD, PhD.
Advertisement
In this video, Susan F. Slovin, MD, PhD, discusses takeaways of her presentation on immunotherapy in advanced prostate cancer, which was given at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, and upcoming research. Slovin is a medical oncologist at the Memorial Sloan Kettering Cancer Center in New York City, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA updates in urology: May 2026
4
FDA approves cefepime and zidebactam for complicated UTI
5











